Please login to the form below

macular oedema

This page shows the latest macular oedema news and features for those working in and with pharma, biotech and healthcare.

The lead molecule of this partnership is THR-149, a novel plasma kallikrein inhibitor, for the treatment of diabetic macular oedema.

After Lucentis setback, Novartis trumpets data on follow-up drug

The experimental therapy – called brolucizumab (RTH258) – showed its was superior to a Bayer and Regeneron’s Eylea (aflibercept) in tackling a key disease activity marker in age-related macular degeneration (AMD), ... In addition to nAMD, Novartis
Regeneron and Bayer drop AMD combination

Abandon plans after disappointing phase II trial results. Regeneron has abandoned a combination therapy for age-related macular degeneration after disappointing phase II data, handing an advantage to would-be rival ... advance the duo into phase III in
Lucentis claims speedy FDA review for myopia complication

in the EU myopic CNV market, adding to their rivalry in other indications such as wet age-related macular degeneration and diabetic macular oedema.
NICE backs Bayer’s Eylea as first-line BRVO treatment

This treatment continues to achieve positive results in real-life clinical practice, similar to that demonstrated in clinical trials, and we hope that this will continue for patients with macular oedema ... its rivals in macular oedema Roche's Avastin
NICE gives Bayer's Elyea a provisional 'no' for first-line use

The provisional guidance in NICE's Appraisal Consultation Document only recommends Eylea in visual impairment in adults caused by macular oedema if laser photocoagulation has not been beneficial or is not ... NICE has previously recommended Eylea to

More from news
Approximately 8 fully matching, plus 36 partially matching documents found.

Diagnosed Anywhere

The system creates an immediate, reliable assessment for diabetic retinopathy, including macular oedema, during a routine office visit in a primary care setting.
Medius Deal Watch table for February 2015

Majority acquisition. 380. Pfenex/ Hospira. PF582 - LUCENTIS biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema.
Allergan and taking a specialised approach

spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Add my company

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...